Hospices Civils de Lyon, Service de Biostatistique, Lyon, F-69003, France.
Brief Bioinform. 2011 Mar;12(2):176-86. doi: 10.1093/bib/bbq019. Epub 2010 Jun 9.
The identification of new diagnostic or prognostic biomarkers is one of the main aims of clinical cancer research. In recent years there has been a growing interest in using high throughput technologies for the detection of such biomarkers. In particular, mass spectrometry appears as an exciting tool with great potential. However, to extract any benefit from the massive potential of clinical proteomic studies, appropriate methods, improvement and validation are required. To better understand the key statistical points involved with such studies, this review presents the main data analysis steps of protein mass spectra data analysis, from the pre-processing of the data to the identification and validation of biomarkers.
鉴定新的诊断或预后生物标志物是临床癌症研究的主要目标之一。近年来，人们越来越关注使用高通量技术来检测此类生物标志物。特别是，质谱分析似乎是一种令人兴奋的具有巨大潜力的工具。然而，要从临床蛋白质组学研究的巨大潜力中获得任何益处，就需要适当的方法、改进和验证。为了更好地理解此类研究涉及的关键统计要点，本文综述了蛋白质质谱数据分析的主要数据分析步骤，从数据的预处理到生物标志物的鉴定和验证。
